C
에이프로젠
007460KOSPI기타 금속 가공제품 제조업46.0 / 100
Reference Date: 2026-04-13
Financial Score13.5 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure14.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Slightly up 3.6% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Aprogen operates major businesses in hardfacing, steel sales, nuclear insulation, pharmaceuticals, and biopharmaceuticals, maintaining a leading position in the domestic hardfacing market. The biopharmaceutical division focuses on developing biosimilars and new drugs, successfully selling Remicade biosimilars in the Japanese market.
Number of Employees
311people
Average Salary
52.0M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 18.214.0Point
PBR
0.23Industry Average 0.897.0Point
Half of industry avg (excellent)
ROE
-31.28Industry Average 1.990.0Point
Well below industry avg
Debt Ratio
16.33Industry Average 12.412.0Point
Higher than industry avg (caution)
Trend 2023~20250.5 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼10.9% (2-year basis)
Operating Profit Growth Rate
0.5 / 3
Avg ▼3.9% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -25.6% (declining, 3yr)
Detailed News Sentiment
3 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50
- Neutral삼천당제약, 코스닥 시총 1위 등극…바이오 랠리 기대감 '꿈틀'[바이오...
삼천당제약이 코스닥 시가총액 1위에 등극하며 바이오 랠리에 대한 기대감이 커지고 있다는 내용입니다.
Detailed Momentum
52-week position1.0Point
Near 52w low (5%, downtrend)
Current 317Won52-week high 91052-week low 280
1-month return4.0Point
1m +3.59% (slight rise)
Volume trend1.0Point
Volume dry-up
Detailed Disclosure
15 totalPositive 2Neutral 13Negative 0
- Neutral[기재정정]주요사항보고서(전환사채권발행결정)2026-04-10
- Neutral주식등의대량보유상황보고서(일반)2026-04-03
- Positive주요사항보고서(유상증자결정)2026-04-02
- Neutral[기재정정]투자판단관련주요경영사항2026-03-31
- Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31